1. June 23, 2020

    Coronavirus and the battle of the FAMHP: thorough work so that every patient can be treated

    Source: FAMHP

    Sinds het begin van de coronapandemie werken de teams van het FAGG keihard om de ziekenhuizen en apotheken te ondersteunen bij hun problemen met de bevoorrading van geneesmiddelen. Hieronder volgt een overzicht van de maatregelen die het FAGG heeft genomen om de geneesmiddelenvoorraad in België te garanderen. 

    Depuis le début de la pandémie de coronavirus, les équipes de l’AFMPS travaillent à un rythme intense pour soutenir les hôpitaux et les pharmacies face aux difficultés d’approvisionnement en médicaments. Voici un aperçu des mesures mises en place par l’AFMPS pour garantir les stocks de médicaments en Belgique.

    Read more

  2. June 23, 2020

    Coronavirus : first COVID-19 vaccine trial authorized in Belgium

    Source: FAMHP

    The Federal Agency for Medicines and Health Products (FAMHP) has authorized the first clinical trial evaluating a vaccine against COVID-19 in Belgium. This is the candidate vaccine from the German biotech firm CureVac.

    Read more

  3. June 23, 2020

    Reaction of the FAMHP to information in the media on serological tests

    Source: FAMHP

    Reactie van Xavier De Cuyper, administrateur-generaal van het FAGG.

    Réaction de Xavier De Cuyper, administrateur général de l’AFMPS.

    Read more

  4. June 23, 2020

    Coronavirus: the FAMHP is allowing an extension of the payment deadlines expiring before 01.07.2020.

    Source: FAMHP

    In the context of the coronavirus crisis, the FAMHP is extending all payment periods expiring before 01.07.2020 for all its customers.

    Read more

  5. June 2, 2020

    EMA warns against use of unproven cell therapies

    Heard from FAMHP

    The Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA) advises patients and citizens not to use unregulated cell therapies, which may be unsafe or ineffective.

    Read more

  6. June 2, 2020

    Coronavirus: reminder of the risks of chloroquine and hydroxychloroquine

    Heard from FAMHP

    The FAMHP restates the risks linked to the use of chloroquine and hydroxychloroquine to treat COVID-19 following the publication of a retrospective analysis of a patient monitoring register in the medical journal The Lancet on 22 May 2020. The analysis did not highlight any benefits from these drugs in patients with COVID-19 and revealed adverse cardiovascular effects.

    Read more

  7. June 2, 2020

    Coronavirus: updated guidelines for verifying the compliance and suitability of surgical face masks

    Heard from FAMHP

    The FAMHP has issued guidelines for checking the compliance and suitability of surgical face masks during the COVID-19 crisis. The guidelines are intended for companies, institutions and authorities that order, sell or use these masks.

    Read more

  8. June 2, 2020

    Coronavirus: recommendations for replacing closed suction systems

    Heard from FAMHP

    The FAMHP reminds hospitals of the recommendations for replacing closed suction systems and offers temporary practical advice to help healthcare professionals waiting on a new stock of suction systems.

    Read more

  9. June 2, 2020

    Coronavirus: relaxation of paracetamol measures for pharmacists and patients

    Heard from FAMHP

    Sales of paracetamol remain stable, which is why the restriction of only one box per patient is being lifted. The quotas for pharmaceutical companies and wholesalers have already been abolished. Only the intravenous form remains subject to restriction.

    Read more

  10. June 2, 2020

    The FAMHP web portal - updates to the “My company” and “My activities” applications

    Heard from FAMHP

    In anticipation of the European regulations on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), the FAMHP has updated the “My company” and “My activities” applications in its web portal.

    Read more